Oncternal Therapeutics, Inc. ONCT
At closeDec 2, 2024, 4:00 PM EST
52-week range unavailable
- Market cap
- 1.56M
- Revenue (ttm)
- 2.16M
- Shares out
- 2.96M
- Forward P/E
- -0.05
- Volume
- 644.13K
- Open
- 0.70
- Previous close
- 0.5266
- Day's range
- 0.5266 – 0.70
- Analysts
- Hold
- Price target
- 2.00 (+279.8%)
- Earnings date
- Nov 6, 2024
Key statistics
- Enterprise value
- -12.83M
- PEG ratio
- 0.00
- Price / sales
- 0.72
- Price / book
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 176.00%
- Free cash flow
- -17.68M
- Total cash
- 14.58M
- Total debt
- 191.00K
- Return on equity
- -149.86%
- Short % of float
- 0.50%
- 50-day average
- 1.06
- 200-day average
- 5.13
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 6, 2024
Expected Nov 6, 2024. Consensus EPS estimate -3.47.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -3.22 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -3.03 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -2.88 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -3.09 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -3.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -3.40 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jan 29, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oncternal.com
News
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board 
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations 
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript 
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates 
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results 
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results 
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit 
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Your note
Sign in to keep a note on ONCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREITMEYER JAMES B | Chief Executive Officer | Purchase | Apr 13, 2023 | 0 |
| HALE DAVID F | Director | Purchase | Feb 22, 2024 | 0 |
| KAUFMANN GUNNAR F | Officer | Purchase | Jun 13, 2023 | 94,726 |
| LEAVITT CHASE C. | General Counsel | Purchase | Apr 12, 2023 | 106,901 |
| VINCENT RICHARD G. | Chief Financial Officer | Purchase | Apr 12, 2023 | 163,219 |
| WILLS ROBERT JAMES | Director | Purchase | Apr 7, 2024 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.73% | 139,884 | 73.66K | Sep 29, 2024 |
| Millennium Management Llc | 2.07% | 61,205 | 32.23K | Sep 29, 2024 |
| Blackrock Inc. | 1.34% | 39,706 | 20.91K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 25,879 | 13.63K | Sep 29, 2024 |
| Pasadena Private Wealth, LLC | 0.84% | 25,000 | 13.16K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.60% | 17,905 | 9.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.65% | 107,989 | 56.87K | Jun 29, 2024 |
| Vanguard Extended Market Index Fund | 1.05% | 31,061 | 16.36K | Jun 29, 2024 |
| Fidelity Extended Market Index Fund | 0.51% | 15,005 | 7.90K | Sep 29, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.49% | 14,404 | 7.58K | Jul 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Small Cap ETF | 0.30% | 8,864 | 4.67K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 4,027 | 2.12K | Sep 29, 2024 |